Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE
Por um escritor misterioso
Descrição
Hobson ENT - I am exceedingly proud to have been involved in this multicentre, phase 3 RCT on Mepolizumab which is a new class of biological agent used of the treatment of
Study Results NUCALA (mepolizumab) for HCPs
Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Respiratory Medicine
Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: A systematic review and network meta-analysis - ScienceDirect
Mepolizumab for chronic rhinosinusitis with nasal polyps: Treatment efficacy by comorbidity and blood eosinophil count - ScienceDirect
Study Results NUCALA (mepolizumab) for HCPs
Mepolizumab for chronic rhinosinusitis with nasal polyps: Treatment efficacy by comorbidity and blood eosinophil count - ScienceDirect
Chronic Rhinosinusitis With Nasal Polyps: Quality of Life in the Biologics Era - ScienceDirect
Mepolizumab for chronic rhinosinusitis with nasal polyps - The Lancet Respiratory Medicine
Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Respiratory Medicine
Mepolizumab improvements in health-related quality of life and disease symptoms in a patient population with very severe chronic rhinosinusitis with nasal polyps: psychometric and efficacy analyses from the SYNAPSE study
Frontiers Differential nasal swab cytology represents a valuable tool for therapy monitoring but not prediction of therapy response in chronic rhinosinusitis with nasal polyps treated with Dupilumab
de
por adulto (o preço varia de acordo com o tamanho do grupo)
